Literature DB >> 26693954

Galectin-3 Predicts Left Ventricular Remodeling of Hypertension.

Yongwei Yao1, Dongli Shen1, Rong Chen1, Chunyang Ying1, Chenghua Wang1, Junfang Guo1, Guohui Zhang1.   

Abstract

Previous studies have suggested that galectin-3 is an important mediator of cardiac fibrosis. The aim of this study was to investigate the utility of galectin-3 in identifying early left ventricular remodeling (LVRM) in patients with hypertension. A total of 107 patients with hypertension and 108 controls were enrolled in this study. The levels of galectin-3 were significantly greater in hypertension patients with LVRM compared with those without LVRM. Multivariate regression analysis demonstrated that body mass index and galectin-3 were independent predictors of LVRM in the hypertension group. Only left ventricular mass was independently correlated with serum galectin-3 levels in patients with hypertension. The receiver operating characteristic analysis showed an area under the curve for galectin-3 of 0.698 (P<.001), with an optimal cutoff of 9.43 ng/mL. Therefore, galectin-3 is independently correlated with LVRM and can be regarded as a valuable biomarker of early cardiac remodeling of hypertension. ©2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26693954      PMCID: PMC8031497          DOI: 10.1111/jch.12757

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  36 in total

1.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

Authors:  Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

Review 2.  The progression of hypertensive heart disease.

Authors:  Mark H Drazner
Journal:  Circulation       Date:  2011-01-25       Impact factor: 29.690

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 4.  Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies.

Authors:  C Cuspidi; C Sala; F Negri; G Mancia; A Morganti
Journal:  J Hum Hypertens       Date:  2011-11-24       Impact factor: 3.012

5.  Galectin-1 and galectin-3 in chronic pancreatitis.

Authors:  L Wang; H Friess; Z Zhu; L Frigeri; A Zimmermann; M Korc; P O Berberat; M W Büchler
Journal:  Lab Invest       Date:  2000-08       Impact factor: 5.662

6.  Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

Authors:  Dirk J A Lok; Peter Van Der Meer; Pieta W Bruggink-André de la Porte; Erik Lipsic; Jan Van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2010-02-04       Impact factor: 5.460

Review 7.  Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches.

Authors:  Efrain Reisin; Avanelle V Jack
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

8.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study.

Authors:  M S Lauer; K M Anderson; W B Kannel; D Levy
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

9.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

10.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis.

Authors:  Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Francoise Poirier; Francesco P Russo; John P Iredale; Christopher Haslett; Kenneth J Simpson; Tariq Sethi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

View more
  9 in total

1.  Galectin-3 Predicts Left Ventricular Remodeling of Hypertension.

Authors:  Yongwei Yao; Dongli Shen; Rong Chen; Chunyang Ying; Chenghua Wang; Junfang Guo; Guohui Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738

2.  Galectin-3 and Hypertensive Heart Disease.

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-23       Impact factor: 3.738

3.  Multiomic Profiling in Black and White Populations Reveals Novel Candidate Pathways in Left Ventricular Hypertrophy and Incident Heart Failure Specific to Black Adults.

Authors:  Daniel H Katz; Usman A Tahir; Debby Ngo; Mark D Benson; Yan Gao; Xu Shi; Matthew Nayor; Michelle J Keyes; Martin G Larson; Michael E Hall; Adolfo Correa; Sumita Sinha; Dongxiao Shen; Matthew Herzig; Qiong Yang; Jeremy M Robbins; Zsu-Zsu Chen; Daniel E Cruz; Bennet Peterson; Ramachandran S Vasan; Thomas J Wang; James G Wilson; Robert E Gerszten
Journal:  Circ Genom Precis Med       Date:  2021-05-21

Review 4.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

Review 5.  A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations.

Authors:  Ewa Smereczyńska-Wierzbicka; Radosław Pietrzak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2022-04-05       Impact factor: 3.390

6.  Trend of Galectin-3 Levels in Patients with Non-ST-Elevation and ST-Elevation Myocardial Infarction.

Authors:  Branka Mitić; Andriana Jovanović; Valentina N Nikolić; Dragana Stokanović; Olivera M Andrejić; Rada M Vučić; Milan Pavlović; Aleksandra Ignjatović; Stefan Momčilović
Journal:  Medicina (Kaunas)       Date:  2022-02-14       Impact factor: 2.430

Review 7.  The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.

Authors:  Grażyna Sygitowicz; Agata Maciejak-Jastrzębska; Dariusz Sitkiewicz
Journal:  Biomolecules       Date:  2021-12-29

8.  Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus.

Authors:  Volker H Schmitt; Jürgen H Prochaska; Annegret S Föll; Andreas Schulz; Karsten Keller; Omar Hahad; Thomas Koeck; Sven-Oliver Tröbs; Steffen Rapp; Manfred Beutel; Norbert Pfeiffer; Konstantin Strauch; Karl J Lackner; Thomas Münzel; Philipp S Wild
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

9.  Evaluation of Galectin-3 Plasma Concentration in Adolescents with Ventricular Arrhythmia.

Authors:  Radosław Pietrzak; Tomasz M Książczyk; Elżbieta Górska; Łukasz A Małek; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-03-02       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.